Ublituximab for Myasthenia Gravis

This trial tests a drug called ublituximab to determine its effectiveness for people with myasthenia gravis (MG) who have already improved with efgartigimod. MG causes muscles to tire easily and weaken. The study consists of two parts: some participants will receive either ublituximab or a placebo (a look-alike with no active medicine), while others will receive only ublituximab. This trial may suit those diagnosed with MG, who have found efgartigimod helpful, and experience symptoms like muscle weakness beyond the eyes. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that ublituximab is generally safe for people. Studies found that common side effects are mild and may include fever, chills, and low blood pressure, especially with the first dose. Ublituximab also has approval for treating multiple sclerosis, indicating its safety for humans. Additionally, one study showed that ublituximab safely reduced symptoms in people with myasthenia gravis, an autoimmune condition. Overall, the evidence suggests that while minor side effects may occur, ublituximab is considered safe for human use.¹²³⁴⁵

Ublituximab is unique because it targets CD20-positive B cells in the immune system, which play a crucial role in the development of myasthenia gravis, a condition that causes muscle weakness. Unlike current treatments, such as corticosteroids and acetylcholinesterase inhibitors, which primarily manage symptoms, ublituximab may offer a more direct approach by modifying underlying immune processes. Researchers are excited about this treatment because it has the potential to provide longer-lasting relief and reduce the frequency of flare-ups by targeting the disease at its source.

Research has shown that ublituximab might help treat myasthenia gravis (MG). In an earlier study, 82% of patients experienced significant improvement in daily tasks, with an average increase of more than 4 points in their MG-ADL score, which measures how well MG patients can perform daily activities. This suggests that ublituximab could make daily life easier for people with MG. In this trial, participants will receive either ublituximab or a matching placebo during the randomized controlled period, while non-responders from the induction period will receive ublituximab in the open-label period. Additionally, other studies have found that treatments working in similar ways, like complement inhibitors, are effective for MG. These findings provide promising evidence that ublituximab could help manage MG symptoms.¹³⁶⁷⁸